Health and Healthcare
Health and Healthcare Articles
Peanut allergy is a serious and dangerous, but one biotech may hold the answer that could lead to to a 100% or 200% gain as its peanut allergy drug is expected to become more than just a blockbuster...
Published:
Stealth Bio stock more than doubled on Tuesday after the company announced a critical update from the FDA.
Published:
Co-Diagnostics is a small-cap stock that is far from a household name, but it has received much added exposure of late.
Published:
Tilray released fourth-quarter financial results after the closing bell on Monday. The company said that it had a net loss of $0.62 per share and $46.94 million in revenue, compared with consensus...
Published:
The analysts at its underwriting firms are quite positive on Beam Therapeutics, now that its post-IPO quiet period has come to an end.
Published:
Last Updated:
Forty Seven shares skyrocketed on Monday after the company announced that it would be acquired by Gilead Sciences. But is Gildead paying too much?
Published:
Mylan stock pulled back on Friday after it reported mixed fourth-quarter financial results late Thursday.
Published:
Many of the larger biotechnology and pharmaceutical companies have changed strategies from making acquisitions of speculative biotech outfits. In many cases it is far cheaper to just partner up with...
Published:
Teladoc Health is a company that may actually be winning because of the coronavirus outbreak, even if it likely hasn't seen much of a boost from the virus on its business yet.
Published:
The February 14 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
Published:
The February 14 short interest data has been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.
Published:
Novavax shares made a big step forward on Wednesday after the firm provided an update on its treatment for COVID-19.
Published:
Gilead Sciences stock surged while the broader market was battered on reports that a senior official from the World Health Organization said that Gilead's remdesivir may currently be the best bet on...
Published:
The broad markets are getting crushed on Monday on renewed fears of the spread of the coronavirus (Covid-19). But a handful of stocks were acting as a natural hedge to the virus news.
Published:
Karyopharm Therapeutics shares made a handy gain on Wednesday after the firm secured a key FDA nod for its relapsed or refractory diffuse large B-cell lymphoma treatment.
Published:
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.